AstraZeneca has paused its £200m expansion in Cambridge, halting its entire £650m UK investment plan announced in March 2024.
The Cambridge project was expected to create 1,000 jobs, following the earlier cancellation of a £450m Merseyside vaccine facility.
A spokesperson said the company constantly reassesses investment needs and confirmed the expansion is paused without further comment.
In contrast, AstraZeneca plans $50bn in US investments by 2030, funding facilities in Virginia, Maryland, Massachusetts, California, Indiana, and Texas.
Merck also scrapped a £1bn London research centre, laying off 125 scientists, while Eli Lilly put its £279m London lab on hold.
Sir John Bell warned major pharmaceutical companies are halting UK investment due to an unattractive business environment.
Sanofi called for a clear government plan to make the UK competitive for life sciences investments.
The sector is pressing the NHS to lower the clawback rate from nearly 23% to single digits, aligning with European standards.
Industry leaders stress urgent action is needed to support UK life sciences and sustain pharmaceutical research and development.
AstraZeneca Pauses £200m Cambridge Expansion, Stalling UK Investments
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.